Debiopharm is teaming up with researchers at Yale University to develop Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

